EditorialTreating Hepatitis C: Are Children the Same as Adults?
References (30)
- et al.
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
Gastroenterology
(2005) - et al.
Recombinant interferon-alfa therapy in children with chronic hepatitis C
Hepatology
(1995) - et al.
Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C
Hepatology
(2002) - et al.
High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin
J Hepatol
(2010) - et al.
Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice
Toxicol Appl Pharmacol
(1980) - et al.
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
Hepatology
(2003) - et al.
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
J Hepatol
(2005) - et al.
Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease
Gastroenterology
(2008) - et al.
Factors influencing early virologic response in children with chronic hepatitis C treated with pegylated interferon and ribavirin
Hepatol Res
(2005) - et al.
High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin
J Hepatol
(2010)
Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents
Ann Hepatol
Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?
Ann Intern Med
Hepatitis C comorbidities affecting the course and response to therapy
World J Gastroenterol
Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review
World J Gastroenterol
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Nature
Cited by (4)
Diagnosis and management of hepatitis C virus-infected children
2011, Pediatric Infectious Disease JournalCitation Excerpt :Recent studies have identified host genetic polymorphisms within the IL28B promoter region that are strongly associated with SVR when patients are treated with combination therapy; the association is so powerful that it may lead to a reevaluation of current treatment paradigms.16,20,21 There is no consensus on which children with HCV should be treated and when treatment should be initiated.3,13,16,22 Proponents of more immediate therapy argue that the advantages of treating a child are reduction of long-term morbidity, cost-effectiveness on a drug-per-weight basis, and elimination of the virus before life events or behaviors that promote transmission (pregnancy and delivery, or intravenous drug use).
Chronic hepatitis C in children: Problems and prospects
2014, Vestnik Rossiiskoi Akademii Meditsinskikh Nauk
Conflicts of interest The authors disclose no conflicts.